Showing results (2291-2300 of 2,317) with videos related to
Sort By:
Pageof 232
Lung Cancer (Amsterdam, Netherlands)|June 28, 2020
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA studyShun Lu, Gongyan Chen, Yuping Sun, et al.Nature Medicine|January 6, 2025
Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trialYuankai Shi, Jian Fang, Ligang Xing, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 20, 2022
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label StudyShun Lu, Yiping Zhang, Guojun Zhang, et al.Lung Cancer (Amsterdam, Netherlands)|August 1, 2024
Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC: Final overall survival results from a phase 2 trialShun Lu, Yiping Zhang, Guojun Zhang, et al.JAMA Oncology|November 14, 2024
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical TrialYing Cheng, Wei Zhang, Lin Wu, et al.Cell Reports. Medicine|May 7, 2025
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutationYan Xu, James Chih-Hsin Yang, Yanqiu Zhao, et al.Journal for Immunotherapy of Cancer|November 28, 2024
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 studyCaicun Zhou, Gongyan Chen, Yunchao Huang, et al.Cancer Biology & Medicine|May 24, 2019
Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of Clinical OncologyXuchao Zhang, Zhiyong Liang, Shengyue Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2024
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 StudyNatasha B Leighl, Hiroaki Akamatsu, Sun Min Lim, et al.ACS Nano|March 23, 2022
A Chirality-Based Quantum LeapClarice D Aiello, John M Abendroth, Muneer Abbas, et al.Pageof 232